文献速递脑血管病

DEFUSE 3 中不符合 DAWN 标准的患者接受取栓治疗的分析

DEFUSE 3 Non-DAWN Patients.
PubMed 文献 · Stroke · 2019-01-01

本研究将 DAWN 试验入组标准应用于 DEFUSE 3 数据,识别出 71 例不符合 DAWN 标准的患者,分析其取栓效果。结果显示,梗死核心过大但小于 70 mL 的患者仍能从取栓中获益;NIHSS 6-9 分患者取栓获益仅呈趋势。

要点

  • 梗死核心过大(>DAWN 标准)但核心体积<70 mL 的患者仍可从取栓中获益
  • NIHSS 6-9 分患者取栓功能预后获益仅呈趋势,需更多证据
  • 核心-临床不匹配选择范式或可放宽核心体积阈值

核心结论

  • 梗死核心体积<70 mL 但超过 DAWN 标准的患者接受取栓仍可获益。
  • NIHSS 6-9 分患者取栓获益仅呈趋势,与整体 DEFUSE 3 人群不同。

研究设计与样本

  • 将 DAWN 试验入组标准应用于 DEFUSE 3 患者数据,识别不符合 DAWN 标准的患者(DEFUSE 3 non-DAWN)。
  • 共 71 例 DEFUSE 3 non-DAWN 患者,其中 31 例 NIHSS 6-9 分,33 例核心过大,13 例病前 mRS 2 分(部分患者符合多条)。

主要发现

  • 核心过大患者 24 小时梗死体积中位数 119 mL(IQR 74.6-180),核心非过大患者为 31.5 mL(IQR 17.6-64.3),P<0.001。
  • 核心过大患者取栓较其他 non-DAWN 患者功能预后获益(OR 20.9;CI 1.3-337.8)。
  • NIHSS 6-9 组与 NIHSS≥10 组比较,mRS 0-2 比例分别为 74% 与 22%(P<0.001),死亡率分别为 6% 与 23%(P=0.024)。
  • NIHSS 6-9 患者取栓较其他 non-DAWN 患者功能预后获益趋势(OR 1.86;CI 0.36-9.529)。

关键数值与推荐

  • DAWN 排除原因包括:梗死核心过大、NIHSS 6-9 分、病前 mRS 2 分。
  • 核心过大患者 24 小时梗死体积中位数 119 mL,核心非过大患者 31.5 mL(P<0.001)。
  • NIHSS 6-9 组 mRS 0-2 达 74%,NIHSS≥10 组为 22%(P<0.001);死亡率分别为 6% 与 23%(P=0.024)。
  • 核心过大患者取栓功能预后 OR 20.9(CI 1.3-337.8);NIHSS 6-9 患者 OR 1.86(CI 0.36-9.529)。

临床怎么用

  • 对于发病 6-24 小时前循环大血管闭塞患者,若梗死核心体积<70 mL 但超过 DAWN 标准,仍可考虑取栓。
  • NIHSS 6-9 分患者取栓获益证据尚不充分,需个体化决策。

局限性

  • 为 DEFUSE 3 数据的亚组分析,样本量较小(71 例),部分亚组事件数少。
  • NIHSS 6-9 组取栓获益仅呈趋势,置信区间宽,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- DAWN (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) established thrombectomy for patients with emergent large vessel occlusions presenting 6 to 24 hours after symptom onset. Given the greater inclusivity of DEFUSE 3, we evaluated the effect of thrombectomy in DEFUSE 3 patients who would have been excluded from DAWN. Methods- Eligibility criteria of the DAWN trial were applied to DEFUSE 3 patient data to identify DEFUSE 3 patients not meeting DAWN criteria (DEFUSE 3 non-DAWN). Reasons for DAWN exclusion in DEFUSE 3 were infarct core too large, National Institutes of Health Stroke Scale (NIHSS) score 6 to 9, and modified Rankin Scale score of 2. Subgroups were compared with the DEFUSE 3 non-DAWN and entire DEFUSE 3 cohorts. Results- There were 71 DEFUSE 3 non-DAWN patients; 31 patients with NIHSS 6 to 9, 33 with core too large, and 13 with premorbid modified Rankin Scale score of 2 (some patients met multiple criteria). For core-too-large patients, median 24-hour infarct volume was 119 mL (interquartile range, 74.6-180) versus 31.5 mL (interquartile range, 17.6-64.3) for core-not-too-large patients ( P<0.001). Complications and functional outcomes were similar between the groups. Thrombectomy in core-too-large patients compared with the remaining DEFUSE 3 non-DAWN patients conveyed benefit for functional outcome (odds ratio, 20.9; CI, 1.3-337.8). Comparing the NIHSS 6 to 9 group with the NIHSS ≥10 patients, modified Rankin Scale score 0 to 2 outcomes were achieved in 74% versus 22% ( P<0.001), with mortality in 6% versus 23% ( P=0.024), respectively. For patients with NIHSS 6 to 9 compared with the remaining DEFUSE 3 non-DAWN patients, thrombectomy trended toward a better chance of functional outcome (odds ratio, 1.86; CI, 0.36-9.529). Conclusions- Patients with pretreatment core infarct volumes <70 mL but too large for inclusion by DAWN criteria demonstrate benefit from endovascular therapy. More permissive pretreatment core thresholds in core-clinical mismatch selection paradigms may be appropriate. In contrast to data supporting a beneficial treatment effect across the full range of NIHSS scores in the entire DEFUSE 3 population, only a trend toward benefit of thrombectomy in patients with NIHSS 6 to 9 was found in this small subgroup.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Leslie-Mazwi TM, Hamilton S, Mlynash M, et al. DEFUSE 3 Non-DAWN Patients. Stroke. 2019. PMID: 30727856. doi:10.1161/STROKEAHA.118.023310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。